Visualizando por Autor MALUF, FERNANDO C.
Mostrando reg. 1 a 5 de 5
Fecha de Publicación | Título | Autor(s) |
2021 | A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415) | MALUF, FERNANDO C.; SCHUTZ, FABIO A.; CRONEMBERGER, EDUARDO H., etc. |
2020 | Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) | Andrey Soares; MONTEIRO, FERNANDO SABINO MARQUES; MALUF, FERNANDO C., etc. |
2017 | Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials | MOREIRA, RAPHAEL B.; Marcio Debiasi; FRANCINI, EDOARDO, etc. |
2017 | Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials | MOREIRA, RAPHAEL B.; Marcio Debiasi; FRANCINI, EDOARDO, etc. |
2022 | Survival analysis of the randomized phase II trial to investigate androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415 | MALUF, FERNANDO C.; SOARES, ANDREY; BASTOS, DIOGO ASSED, etc. |